Emerging technologies included with the 10th version of the 1.5T MRI platform include Synergy DLR Clear and Synergy Vision that are geared toward mitigating common challenges with artifacts.
Fujifilm Healthcare has made artifact reduction a key focus of advances with the newly launched 10th version of the Echelon Synergy 1.5T magnetic resonance imaging (MRI) system.
Offering multiple in-bore cameras and the use of real-time tracking from scans to correct motion-compromised raw data, the updated Echelon Synergy device’s combination of Synergy Vision and StillShot artificial intelligence (AI) mitigates motion artifacts, according to Fujifilm Healthcare.
Mitigating artifacts is a key driver of new technological advances included in version 10 of the Echelon Synergy 1.5T MRI system. (Image courtesy of Fujifilm Healthcare.)
The company added that the Echelon Synergy’s inclusion of the AI-powered algorithm DLR Clear addresses the challenging truncation artifact without the need for extended scan time.
“With the v10 (Echelon Synergy), technologists can now apply our RADAR radial sequence with our iterative iRCM IP-Recon processing to mitigate spike artifacts, resulting in clear, high-quality images with reduced motion artifact,” noted Shawn Etheridge, the executive director of modality solutions for Fujifilm Healthcare Americas Corporation.
Fujifilm noted that the upgraded standard software features with version 10 of the Echelon Synergy 1.5T MRI will be provided to current customers free of charge.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.